SCHEMBL3263590

SCHEMBL3263590

c1ccc(Nn2ccc3ccccc32)nc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.58
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
MAPK10 P53779 1/20 0.40
GFER P55789 1/20 0.40
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
PKM P14618 1/20 0.38
CDC7 O00311 1/20 0.37
CDK2 P24941 1/20 0.37
ROCK1 Q13464 1/20 0.37
CXCR4 P61073 1/20 0.37
CDK4 P11802 1/20 0.36
CCND1 P24385 1/20 0.36
FABP1 P07148 1/20 0.36
FABP6 P51161 1/20 0.36
GAA P10253 1/20 0.36
KDM4E B2RXH2 2/20 0.36
LMNA P02545 2/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9445623 0.82 SLC6A2 (0.62) SLC6A2CDC7CDK2ROCK1
SCHEMBL9445652 0.78 SLC6A2 (0.53) SLC6A2CDC7CDK2ROCK1CDK4
SCHEMBL4108710 0.77 RAB9A (0.50) KMT2AMEN1NPC1RAB9APKM
SCHEMBL3139425 0.74 SLC6A2 (1.00) SLC6A2
SCHEMBL9445587 0.73 SLC6A2 (0.48) SLC6A2KMT2AMEN1NPC1CDK2
SCHEMBL3733770 0.72 CA12 (0.42) KMT2AMEN1MAPK10GFERNPC1
SCHEMBL6628128 0.72 SLC6A2 (0.73) SLC6A2KMT2AMEN1RAB9ACDK4
SCHEMBL9311675 0.71 ADRA2A (0.54) KMT2AMEN1MAPK10GFERNPC1
SCHEMBL7610186 0.70 SLC6A2 (0.69) SLC6A2KMT2AMEN1NPC1RAB9A
SCHEMBL6859755 0.70 MEN1 (0.48) KMT2AMEN1MAPK10GFERNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0840609-B1 USE OF UNSUBSTITUTED AND SUBSTITUTED N-(PYRROL-1-YL)PYRIDINAMINES AS ANTICONVULSANT AGENTS AVENTIS PHARMA INC (US) 2002-06-05 EP claimed
US-5776955-A Use of unsubstituted and substituted n-(pyrrol-1-yl)pyridinamines as anticonvulsant agents HOECHST MARION ROUSSEL, INC. 1998-07-07 US claimed
EP-0840609-A1 USE OF UNSUBSTITUTED AND SUBSTITUTED N-(PYRROL-1-YL)PYRIDINAMINES AS ANTICONVULSANT AGENTS HOECHST MARION ROUSSEL, INC. (US) 1998-05-13 EP claimed
WO-1997004777-A1 USE OFF UNSUBSTITUTED AND SUBSTITUTED N-(PYRROL-1-YL)PYRIDINAMINES AS ANTICONVULSANT AGENTS HOECHST MARION ROUSSEL, INC. (US) 1997-02-13 WO claimed
JP-6001787-A None JP disclosed
JP-7053376-A None JP disclosed
EP-2766017-B1 METHODS FOR TREATING A STROKE-RELATED SENSORIMOTOR IMPAIRMENT USING AMINOPYRIDINES ACORDA THERAPEUTICS INC (US) 2020-07-01 EP disclosed
JP-2010120958-A METHOD OF TREATING OF DEMYELINATING DISEASE OR CONDITION AVENTIS PHARMACEUTICALS INC 2010-06-03 JP disclosed
US-20090281147-A1 METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS AVENTIS PHARMACEUTICALS INC. (US) 2009-11-12 US disclosed
US-20090281147-A1 METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS AVENTIS PHARMACEUTICALS INC. (US) 2009-11-12 US disclosed
US-20090270458-A1 METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS AVENTIS PHARMACEUTICALS INC. (US) 2009-10-29 US disclosed
US-20090270458-A1 METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS AVENTIS PHARMACEUTICALS INC. (US) 2009-10-29 US disclosed
US-5185350-A For Alzheimer*s, memory dysfunctions, antidepressants, antiinflammatory agents HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1993-02-09 US disclosed
US-5185350-A For Alzheimer*s, memory dysfunctions, antidepressants, antiinflammatory agents HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1993-02-09 US disclosed
EP-0376155-B1 N-PYRIDINYL-9H-CARBAZOL-9-AMINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1992-08-05 EP disclosed
US-5039811-A Analgesics, antidepressants, memory activators; condensation, reduction HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1991-08-13 US disclosed
EP-0287982-A3 N-(PYRIDINYL)-1H-INDOL-1-AMINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1991-03-27 EP disclosed
US-4970218-A ANALGESIC, ANTIDEPRESSANT, MEMORY ENHANCEMENT HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1990-11-13 US disclosed
US-4880822-A COGNITION ACTIVATORS, ANALGESICS HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1989-11-14 US disclosed
EP-0287982-A2 N-(Pyridinyl)-1H-indol-1-amines, a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1988-10-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281147-A1 METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS PMP22, BDKRB1, BDKRB2 SLC6A2 1049/4885KMT2A 3564/4885MEN1 1949/4885
US-20090270458-A1 METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS PMP22, BDKRB1, BDKRB2 SLC6A2 1049/4885KMT2A 3564/4885MEN1 1949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.